Vesper Bio ApS has been awarded a grant worth $873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease.

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Syntiron US$1.7 million to develop a maternal vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.

Intravacc BV has been awarded funding for up to $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) for the development of a preventive vaccine against Neisseria gonorrhoeae (NG), the bacterium that causes gonorrhea.